Veraxa advances BiTAC dual-targeting platform; hires CFO Raju Willener

Veraxa Biotech AG (NASDAQ:VRXA) is advancing its oncology pipeline with BiTAC, a dual-targeting platform intended to trigger cytotoxicity only when two tumor antigens are engaged to improve tumor selectivity. The company has appointed Raju Willener as CFO to steer its finance and capital markets strategy.